Theolytics

Theolytics is a United Kingdom biotechnology company based in Oxford that is developing next-generation, systemically deliverable oncolytic immunotherapies for cancers of high unmet need. The company's core scientific premise is that many advanced solid tumours are protected by a dense and complex tumour microenvironment — including cancer-associated fibroblasts (CAFs) — which limits drug delivery, suppresses immune response and enables disease progression, reducing the effectiveness of both targeted therapies and immunotherapies. Theolytics aims to break through that barrier using engineered oncolytic adenoviruses. The company's discovery engine is its Adenovo™ platform, which interrogates and refines vast libraries of viral variants against clinically relevant human models. According to the company, this platform and its 100-million-variant library allow it to identify candidates with attributes that matter clinically — selective replication, systemic stability, tissue tropism, manufacturability and immune interplay — and to tailor oncolytic adenoviruses for specific patient populations. Theolytics describes its approach as disciplined and data-first, translating complex viral biology into therapies with clear mechanisms and compelling paths to the clinic. Theolytics' lead candidate is THEO-260, described as a novel oncolytic immunotherapy specifically evolved to target stroma-rich tumours. The company has highlighted THEO-260 in advanced ovarian cancer and has stated that it will showcase its innovative oncolytic immunotherapy strategy, including THEO-260, at investor and scientific events. Theolytics positions itself as combining deep virology expertise with high-resolution discovery platforms and translational rigour, with the mission of unlocking the full therapeutic potential of oncolytic adenoviruses and integrating them into patient-centred oncology care. As a private, clinical-stage biotechnology company, Theolytics operates primarily in the research and development of oncology therapeutics rather than as a commercial product brand. Its public communications focus on its pipeline, its Adenovo™ platform, its team and its investors.

Theolytics is a biotechnology company located in Oxford, United Kingdom. Public information about the company is primarily drawn from its own corporate communications, which describe a research and development organisation focused on oncolytic immunotherapies for solid tumours. The company's scientific foundation rests on the observation that advanced solid tumours are frequently protected by a dense and complex tumour microenvironment, including cancer-associated fibroblasts (CAFs). This barrier limits drug delivery, suppresses immune response and enables disease progression, reducing the effectiveness of both targeted therapies and immunotherapies. Theolytics was established to address this problem by developing systemically deliverable immunotherapies based on oncolytic adenoviruses designed to break through the barriers of solid tumours. Central to the company's approach is its Adenovo™ discovery platform. Theolytics states that Adenovo™ interrogates and refines vast libraries of viral variants against clinically relevant human models, and that the platform, together with a 100-million-variant library, moves the company from discovery to impact. The platform is used to identify viral candidates capable of selectively targeting and destroying both cancer cells and the surrounding tumour-supporting stroma, with selection criteria including selective replication, systemic stability, tissue tropism, manufacturability and immune interplay. Theolytics' lead programme is THEO-260, described as a novel oncolytic immunotherapy specifically evolved to target stroma-rich tumours. The company has highlighted THEO-260 in the context of advanced ovarian cancer and has announced plans to showcase its oncolytic immunotherapy strategy, including THEO-260, at investor and scientific events. The company describes its mission as unlocking the full therapeutic potential of oncolytic adenoviruses and bringing forward therapies that integrate into patient-centred oncology care. As of the available evidence, Theolytics is a private, clinical-stage company. Its public materials emphasise its team, its investors, its Adenovo™ platform and its lead candidate rather than commercial products on the market.

• Theolytics announced it would showcase its innovative oncolytic immunotherapy strategy, including THEO-260 in advanced ovarian cancer, at upcoming investor and scientific events.

Clinical-stage biotechnology company developing systemically deliverable oncolytic immunotherapies designed to overcome the tumour microenvironment barrier in solid tumours.

• THEO-260

  Lead candidate; a novel oncolytic immunotherapy specifically evolved to target stroma-rich tumours, highlighted in advanced ovarian cancer.

• Adenovo™ platform

  Discovery engine that interrogates and refines vast libraries of viral variants against clinically relevant human models, supported by a 100-million-variant library.

1. 1Breaking Through The Barrier | Theolyticstheolytics.com
2. 2Company | Theolyticstheolytics.com
3. 3Theolytics (United Kingdom) - Wikidatawikidata.org